A shingles vaccine study is underway in East Tennessee, with AMR Clinical’s Knoxville site enrolling local participants. Developed by Curevo Vaccine, the investigational vaccine, amezosvatein, is designed to prevent shingles with fewer post-vaccination side effects than existing options. The study is in phase 2 and includes two vaccine doses given two months apart. Eligible participants receive high-quality care and may qualify for a stipend.
Watch this news segment to learn:
- How the new shingles vaccine differs from current options
- What to expect if you join the study at AMR Clinical Knoxville
- Who’s eligible and how to sign up locally